The Board of Directors of Livzon Pharmaceutical Group Inc. has authorized a buyback plan on October 30, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
40.62 CNY | -0.54% | +0.17% | +16.02% |
05-14 | Livzon Pharmaceutical Group Cancels Share Options | MT |
04-26 | Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.02% | 4.62B | |
+31.31% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+15.49% | 239B | |
+10.05% | 210B | |
-7.40% | 200B | |
+8.12% | 167B | |
-1.42% | 161B |
- Stock Market
- Equities
- 000513 Stock
- News Livzon Pharmaceutical Group Inc.
- Livzon Pharmaceutical Group Inc. authorizes a Buyback Plan.